The challenges to demonstrating long-term effects of psychostimulant treatment for attention-deficit/hyperactivity disorder

@article{Hazell2011TheCT,
  title={The challenges to demonstrating long-term effects of psychostimulant treatment for attention-deficit/hyperactivity disorder},
  author={Philip L Hazell},
  journal={Current Opinion in Psychiatry},
  year={2011},
  volume={24},
  pages={286–290}
}
  • P. Hazell
  • Published 1 July 2011
  • Medicine, Psychology
  • Current Opinion in Psychiatry
Purpose of review Questions about the long-term effects of psychostimulant medication are frequently raised in the public domain. There is a need to articulate the methodological challenges to addressing this question, both to assist in the interpretation of existing research and to inform future research. Recent findings Two peer-reviewed studies and one published report have attempted to address the issue of long-term effects of psychostimulant medication. One is favourable, one found no… Expand
Long-Term Pharmacotherapy of Adults With Attention Deficit Hyperactivity Disorder: A Literature Review and Clinical Study.
TLDR
Treatment with stimulants and atomoxetine of adults with ADHD has long-term beneficial effects and is tolerated but more longitudinal studies should be performed. Expand
Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: A review of controlled and naturalistic studies
TLDR
Long-term efficacy and safety of the stimulant drugs methylphenidate and amphetamine, as well as the related compound atomoxetine are reviewed, finding stimulant therapy of ADHD has long-term beneficial effects and is well tolerated. Expand
Methylphenidate for attention-deficit/hyperactivity disorder: Too much of a good thing?
TLDR
The review concluded that besides the paucity of data, there was no evidence to suggest that short-term effects of treatment were maintained, and the overall conclusion that ‘methylphenidate may improve ADHD symptomatology’ is measured and cautious. Expand
Effect of Treatment Modality on Long-Term Outcomes in Attention-Deficit/Hyperactivity Disorder: A Systematic Review
TLDR
The combination of pharmacological and non-pharmacological treatment was most consistently associated with improved long-term outcomes and large effect sizes. Expand
Attention deficit hyperactivity disorder in adults
TLDR
Examination of available literature regarding attention deficit hyperactivity disorder in adults found psychological therapy may be beneficial in adults who continue to experience clinically significant symptoms while receiving pharmacotherapy, and these therapies are generally well tolerated. Expand
Effects of Methylphenidate on Acute Math Performance in Children with Attention-Deficit Hyperactivity Disorder
TLDR
The degree of improvement on the RASS and on math performance on MPH was highly correlated and younger children with lower math scores improved most on math scores when given psychostimulants. Expand
Long-Term Treatment Outcome in Adult Male Prisoners With Attention-Deficit/Hyperactivity Disorder: Three-Year Naturalistic Follow-Up of a 52-Week Methylphenidate Trial
TLDR
It is suggested that motivational support and continued medication are important for improved outcome in adult criminal offenders with ADHD after 4 years of methylphenidate treatment. Expand
Assessment and Intervention for Individuals with Attention-Deficit Hyperactivity Disorder
Attention-deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed childhood psychiatric disorders. As our understanding of ADHD has evolved, so have assessment and interventionExpand
Fractionating Executive Functions of Adults With ADHD
TLDR
Adult ADHD patients who were not under the acute effects of medication reported more symptoms related to ADHD, anxiety and depression symptoms and were impaired in the shifting cost measure and phonemic fluency of access to long-term memory. Expand
Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?
TLDR
It is hypothesized that a prospective randomized, double-blind, placebo-controlled, multicenter trial in individuals stratified for cardiovascular risk factors would allow for an optimized risk assessment and hypothesize that such a trial might be a dedicated risk mitigation strategy for public health. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 31 REFERENCES
Long-Term Stimulant Medication Treatment of Attention-Deficit/Hyperactivity Disorder: Results from a Population-Based Study
TLDR
It is demonstrated that the effectiveness of stimulant medication treatment of ADHD provided throughout childhood is comparable to the efficacy of Stimulant treatment demonstrated in clinical trials. Expand
Predictive factors for persistent use and compliance of immediate-release methylphenidate: a 36-month naturalistic study.
TLDR
Clinical outcome of ADHD treatment is heterogeneous: Specific clinical and social predictive parameters for long-term MPH use and compliance can be identified and an accurate tailoring of clinical intervention to the individual child appears crucial for good outcome. Expand
Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study.
TLDR
Risperidone treatment appears to be well tolerated and modestly effective when used in combination with psychostimulants for treatment-resistant aggression in children with ADHD. Expand
3-year follow-up of the NIMH MTA study.
TLDR
By 36 months, the earlier advantage of having had 14 months of the medication algorithm was no longer apparent, possibly due to age-related decline in ADHD symptoms, changes in medication management intensity, starting or stopping medications altogether, or other factors not yet evaluated. Expand
Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment.
TLDR
Same-day saliva methylphenidate assays suggest that nearly half of the parents are inaccurate informants of their child's ADHD medication adherence and that parents may overestimate actual (physiological) adherence, suggesting the need for interventions to improve accuracy of parental report. Expand
The Role of Alpha2-Adrenergic Agonists in Attention-Deficit/Hyperactivity Disorder
TLDR
This review will encompass the clinical study database for novel formulations of alpha2-adrenergic agonists, enabling the reader to appreciate their place in ADHD treatment as well as the potential utility of a combination approach with psychostimulants for patients with complex ADHD. Expand
The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies
TLDR
The results show that estimates of ADHD's persistence rely heavily on how one defines persistence, yet, regardless of definition, the analyses show that evidence for ADHD lessens with age. Expand
The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study.
TLDR
Type or intensity of 14 months of treatment for ADHD in childhood does not predict functioning 6 to 8 years later, and early ADHD symptom trajectory regardless of treatment type is prognostic, implying that children with behavioral and sociodemographic advantage, with the best response to any treatment, will have the best long-term prognosis. Expand
Modifiers of Long-Term School Outcomes for Children with Attention-Deficit/Hyperactivity Disorder: Does Treatment with Stimulant Medication Make a Difference? Results from a Population-Based Study
TLDR
St stimulant treatment of children with AD/HD was associated with improved reading achievement, decreased school absenteeism, and decreased grade retention, and this study provides support for efforts to ensure that children withAD/HD receive appropriate long-term medical treatment. Expand
A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD)
TLDR
ATX and LAS are the most likely drugs to be used as monotherapy in managing adult ADHD, and predictors of combination therapy for LAS and for ATX were modeled for patients covered by commercial plans. Expand
...
1
2
3
4
...